News | Radiation Therapy | December 12, 2019

First Patient Treated with New Proteus ONE Solution at the University of Florida Health Proton Therapy Institute

UFHPTI expands its proton therapy capacity and treatment range

UFHPTI expands its proton therapy capacity and treatment range with the Proteous One

December 12, 2019 — IBA (Ion Beam Applications SA) announced that the University of Florida Health Proton Therapy Institute (UFHPTI) has started the first treatments with its Proteus ONE solution. The Proteus ONE solution comes as a complement of the ProteusPLUS solution, in operations since 2006, to meet the increasing demand of proton therapy treatment.
 
With its open gantry enabling a high patient throughput, the IBA compact proton therapy solution has been installed within 11 months at UFHPTI and includes latest generation precision technologies of pencil beam scanning (PBS) and cone beam CT (CBCT) capabilities as well as the Philips Ambient Experience.
 
At the end of 2019, UFHPTI has treated over 8,500 patients with its Proteus PLUS solution. Since opening in 2006, the center has been treating patients with three gantry rooms and one eye line. With the two IBA Proteus proton therapy solutions, UFHPTI has the ability to treat 25 percent more patients.
 
To date, there are 33 IBA proton therapy centers in operation worldwide of which 10 are compact Proteus ONE systems making it the undisputed market leader in both single and multi-room configurations.
 
Olivier Legrain, chief executive officer of IBA, commented: “We are pleased to see the first patient has begun the treatment with our compact proton therapy solution in Jacksonville and expand further our trustful collaboration with UFHPTI. UFHPTI has been one of the pioneers in proton therapy and will continue to lead its development with exciting innovations coming up. IBA is developing game changing techniques such as Proton ARC1 Therapy and FLASH1 therapy.”
 
Stuart Klein, MHA, executive director of University of Florida Health Proton Therapy Institute, added: “The start of patient treatment with the Proteus ONE marks a major milestone in a multiphase expansion and upgrade project that improves treatment efficiency and technology. Over the last 15 years, we have developed a trusted long-standing partnership with IBA. With this new facility that complements our existing proton therapy system, we can meet the growing demand for proton therapy treatments. We are also eager to play a leading role in the development of new technologies such as Proton Arc Therapy, that will enable us to treat even more patients in the future.”

For more information: www.iba-worldwide.com
 

Related Content

Accuray Incorporated announced that Mercy Hospital St. Louis continues to demonstrate its commitment to improving patient outcomes with the installation of the first CyberKnife M6 System in Missouri at their state-of-the-art David C. Pratt Cancer Center
News | Stereotactic Body Radiation Therapy (SBRT) | February 27, 2020
February 27, 2020 — Accuray Incorporated announced that Mercy
An example of the MRI scans showing long-term and short-term survival indications. #MRI

An example of the MRI scans showing long-term and short-term survival indications. Image courtesy of Case Western Reserve University

News | Magnetic Resonance Imaging (MRI) | February 21, 2020
February 21, 2020 — ...
Arizona State University researchers (in collaboration with Banner MD Anderson Cancer Center) have discovered a biocompatible cost-effective hydrogel that can be used to monitor therapeutic doses of ionizing radiation by becoming more pink with increasing radiation exposure

Arizona State University researchers (in collaboration with Banner MD Anderson Cancer Center) have discovered a biocompatible cost-effective hydrogel that can be used to monitor therapeutic doses of ionizing radiation by becoming more pink with increasing radiation exposure. This picture shows a circle of hydrogel that was irradiated on the left half, which is slightly pink; whereas the right half of the gel is not irradiated and remains colorless.

News | Radiation Therapy | February 18, 2020
February 18, 2020 — More than half of all cancer patients undergo radiation therapy and the dose is critical.
Nuclear imaging equipment growth in 2020
News | Nuclear Imaging | February 14, 2020
February 14, 2020 — The nuclear imaging equipment
Varian announced it has received FDA 510(k) clearance for its Ethos therapy, an Adaptive Intelligence solution. Ethos therapy is an artificial intelligence (AI)-driven holistic solution that provides an opportunity to transform cancer care.
News | Image Guided Radiation Therapy (IGRT) | February 11, 2020
February 11, 2020 — Varian announced it has received FDA 510(k) c
The radiation therapy market is projected to grow in through 2026

Image courtesy of Accuray

News | Proton Therapy | February 10, 2020
February 10, 2020 — Amid technological advancement, and notable research and development activities, the global ...
SIR President Laura Findeiss, M.D., FSIR

SIR President Laura Findeiss, M.D., FSIR

News | Interventional Radiology | February 09, 2020
February 9, 2020 — For some patients, kidney cancer can be effectively treated without surgery, according to the...
Accuray TomoTherapy total body irradiation
News | Radiation Therapy | February 07, 2020
February 7, 2020 — Accuray Incorporated announced that two new studies demonstrate the benefits of the ...
Purdue University-discovered fluorescent markers to target and illuminate cancer during surgery, has announced the results of a multi-institutional Phase 2 clinical trial in which outcomes were improved for 26 percent of patients undergoing pulmonary resection for non-small-cell lung cancer (NSCLC)

A Purdue discovery being developed by On Target Laboratories Inc., illuminates lung cancer cells on a patient during surgery. The “fluorescent markers” help medical professionals identify and remove cancer cells during surgery and is shown to improve outcomes. The technology is beginning Phase 3 clinical trials. (Photo provided by On Target)

News | Molecular Imaging | February 06, 2020
February 6, 2020 — ...